NBIX FY 2019 Earnings Report — Neurocrine Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

Neurocrine Biosciences, Inc.NBIX

FY 2019 Earnings

Reported February 6, 2020

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2019	Prior Q	FY 2018	QoQ Change	YoY Change
Revenue	$788M	—	$451M	—	74.7%
Op. Income	$72M	—	$37M	—	96.5%
Gross Margin	99.1%	—	98.9%	—	0.1pp
Net Margin	4.7%	—	4.7%	—	0.0pp
EPS (Diluted)	$0.39	—	$0.22	—	77.3%
Free Cash Flow	$132M	—	$77M	—	72.7%

Revenue Flow

Item	Amount
REVENUE	$788M
Cost of Revenue	$7M
GROSS PROFIT	$781M
R&D Expenses	$200M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$354M
Other Expenses	$154M
Operating Expenses	$708M
Cost & Expenses	$716M
OPERATING INCOME	$72M
Interest Income	$0
Interest Expense	$32M
Other Income/Expenses	-$26M
INCOME BEFORE TAX	$47M
Income Tax Expense	$10M
Net Income from Continuing Ops	$37M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$37M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$37M
D&A	$7M
EBIT	$79M
EBITDA	$86M
EPS	$0
EPS Diluted	$0

Income Statement

Item	Amount
REVENUE	$788M
Cost of Revenue	$7M
GROSS PROFIT	$781M
R&D Expenses	$200M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$354M
Other Expenses	$154M
Operating Expenses	$708M
Cost & Expenses	$716M
OPERATING INCOME	$72M
Interest Income	$0
Interest Expense	$32M
Other Income/Expenses	-$26M
INCOME BEFORE TAX	$47M
Income Tax Expense	$10M
Net Income from Continuing Ops	$37M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$37M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$37M
D&A	$7M
EBIT	$79M
EBITDA	$86M
EPS	$0
EPS Diluted	$0

Cash Flow Statement

Item	Amount
Net Income	$37M
Depreciation & Amortization	$7M
Stock-Based Compensation	$75M
Deferred Income Tax	$0
Other Non-Cash Items	$32M
Change in Working Capital	-$5M
OPERATING CASH FLOW	$147M
Capital Expenditure	-$15M
Acquisitions (Net)	$0
Purchases of Investments	-$866M
Sales/Maturities of Investments	$670M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$211M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$5M
NET CASH FROM FINANCING	$32M
FREE CASH FLOW	$132M
Net Change in Cash	-$32M

Balance Sheet

Item	Amount
Cash & Equivalents	$112M
Short-Term Investments	$558M
Net Receivables	$127M
Inventory	$17M
Other Current Assets	$17M
TOTAL CURRENT ASSETS	$831M
PP&E (Net)	$116M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$356M
Tax Assets	$0
Other Non-Current Assets	$3M
TOTAL NON-CURRENT ASSETS	$475M
TOTAL ASSETS	$1.3B
Account Payables	$41M
Short-Term Debt	$409M
Deferred Revenue	$0
Other Current Liabilities	$85M
TOTAL CURRENT LIABILITIES	$565M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$17M
TOTAL NON-CURRENT LIABILITIES	$104M
TOTAL LIABILITIES	$669M
Common Stock	$92.0K
Additional Paid-In Capital	$1.8B
Retained Earnings	-$1.1B
Treasury Stock	$0
Accum. Other Comp. Income	$1M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$637M
Minority Interest	$0
TOTAL EQUITY	$637M
TOTAL LIABILITIES & EQUITY	$1.3B
Total Debt	$496M
Net Debt	$383M